Skip to content
Assyro AI
FDA Purple Book product · Biosimilar 351(k)

Nivestym

filgrastim-aafi

Nivestym, BLA 761080, is listed in the FDA Purple Book as a 351(k) biosimilar. This page consolidates 4 exact FDA presentation rows, and FDA names Neupogen as its reference product. It separates the BLA applicant from any unverified manufacturer and does not infer clinical labeling, pharmacy substitution, commercial availability, or patent conclusions.

351(k) BiosimilarBLA 761080 4 presentationsRxLicensed Hospira Inc., a Pfizer Company
Approved
Jul 20, 2018
License type
351(k) Biosimilar
Marketing
Rx
Listed patents
0
Nivestym (filgrastim-aafi) is a Biosimilar 351(k) referencing filgrastim, licensed under a 351(k) BLA in 2018; the Purple Book lists Hospira Inc., a Pfizer Company as the BLA applicant, not necessarily the manufacturer or commercial supplier.

Sourced from the FDA Purple Book · verified Oct 08, 2026

What this Purple Book record establishes

Regulatory interpretation
Ask AI

BLA number

761080

Regulatory role

351(k) biosimilar

Applicant

Hospira Inc., a Pfizer Company

Applicant is not automatically the physical manufacturer.

Presentations

4

Exact FDA presentation rows under this BLA.

Approval

Jul 20, 2018

Reference product

Neupogen

Nivestym is an FDA-licensed biosimilar without an interchangeability designation in this record.

Nivestym was licensed through the 351(k) pathway as biosimilar to Neupogen.

Substitution boundary

Biosimilar status alone is not an FDA interchangeability designation and does not establish automatic pharmacy substitution.

Key dates

Licensure & exclusivity
Ask AI
  1. Approval

    Approval date of this BLA submission.

    Jul 20, 2018

    8 yr 6 mo ago

  2. Today

Strengths & presentations

4 FDA presentation rows · BLA 761080
Ask AI

Strength

300MCG/ML

Dosage form

Injection

Route

Intravenous, Subcutaneous

Presentation

Single-Dose Vial

Center

CDER

License number

1974

Product number

001

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Exact presentation matrix

One row per FDA presentation under this exact BLA. Missing cells remain unavailable rather than being borrowed from another product.

Exact FDA Purple Book presentation rows for this BLA
ProductStrengthDosage formRoutePresentationLicensureMarketing
001300MCG/MLInjectionIntravenous, SubcutaneousSingle-Dose VialLicensedRx
002480MCG/1.6MLInjectionIntravenous, SubcutaneousSingle-Dose VialLicensedRx
003300MCG/0.5MLInjectionSubcutaneousPre-Filled SyringeLicensedRx
004480MCG/0.8MLInjectionSubcutaneousPre-Filled SyringeLicensedRx

Exact-source evidence coverage

Labeling & approval review

Current product label

Candidate awaiting exact-BLA match

FDA exposes a label link on this Purple Book row, but labeling content remains unavailable until the document is independently matched to this exact BLA and its presentations.

Inspect FDA label candidate

FDA approval evidence

Exact-source research required

No independently matched exact-BLA FDA approval letter or review package is stored, so product-specific biosimilarity or switching evidence is not summarized.

Human review pending

Automated BLA-level interpretation has not been marked human-reviewed. The research queue contains 2 exact-source tasks. Labeling and approval-review claims stay unavailable until their own match gate passes.

Reference product family

Biosimilars & interchangeables

Nivestym names Neupogen as its reference product. The comparison below shows locally matched BLA candidates and follow-ons; it does not invent a reference BLA number when FDA did not state one in the loaded row.

Biosimilar of Neupogen

Reference-family comparison

Purple Book comparison of products in this reference family
ProductDesignationBLAApprovedPresentationMarketing
Neupogenfilgrastim351(a) name-matched reference candidate103353Feb 20, 1991300MCG/ML · Intravenous, SubcutaneousRx
Nivestymfilgrastim-aafi351(k) biosimilar761080Jul 20, 2018480MCG/0.8ML · SubcutaneousRx

Published patents

BPCIA patent list
Ask AI

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Practical characteristics and limits

Source-bounded interpretation

Presentation coverage

4 exact FDA presentation rows are consolidated under this BLA rather than split across duplicate pages.

Administration fields

The loaded rows list Intravenous, Subcutaneous and Subcutaneous and Injection; these are regulatory presentation fields, not dosing instructions.

Applicant boundary

Hospira Inc., a Pfizer Company is the listed BLA applicant. The page does not relabel the applicant as manufacturer, labeler, distributor, or commercial supplier without an exact product-specific source.

Regulatory comparison

Nivestym is an FDA-licensed biosimilar without an interchangeability designation in this record. Family comparisons preserve each BLA's own designation and do not use Orange Book therapeutic-equivalence terminology.

Source provenance

FDA Purple Book data
Source kind · Monthly download
Checked Oct 08, 2026
FDA release · September 2026
  • advanced-searchAdvanced Search · Oct 08, 2026
  • monthly-downloadMonthly download · Oct 08, 2026
  • monthly-downloadMonthly download · Sep 21, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

What this record does not establish

  • Purple Book marketing status is a regulatory field, not real-time commercial inventory or launch status.
  • The listed applicant or BLA holder is not automatically the product’s physical manufacturer, labeler, or distributor.
  • Biosimilar status and interchangeability are distinct FDA designations; neither is a therapeutic-equivalence code from the Orange Book.
  • A missing patent or exclusivity row is not proof that no relevant rights exist, and listed patent information is not a freedom-to-operate opinion.
  • Approved uses, dosing, warnings, and clinical evidence require the exact current product label or approval package and are not inferred from the reference product.

Change history

Record versions
  • v8Oct 08, 2026
  • v7Oct 08, 2026
  • v6Sep 21, 2026
  • v5Aug 11, 2026
  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Nivestym: frequently asked questions

Licensure, biosimilar status, exclusivity, and patents for this biologic, from the FDA Purple Book.

Built directly from the FDA Purple Book database of licensed biological products. License types, approval and exclusivity dates, and the patent list match the official FDA record. The Purple Book patent list reflects the statutory BPCIA patent exchange and is not exhaustive.

Related FDA reference tools

Assyro Intelligence

Ask anything about Nivestym

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo